Top-Rated StocksTop-RatedNASDAQ:ARDX Ardelyx (ARDX) Stock Price, News & Analysis $6.11 0.00 (0.00%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$6.15 +0.04 (+0.64%) As of 08/22/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Ardelyx Stock (NASDAQ:ARDX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Ardelyx alerts:Sign Up Key Stats Today's Range$6.08▼$6.2950-Day Range$3.55▼$6.1152-Week Range$3.21▼$7.18Volume3.65 million shsAverage Volume4.67 million shsMarket Capitalization$1.47 billionP/E RatioN/ADividend YieldN/APrice Target$11.50Consensus RatingBuy Company Overview Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts. Read More Ardelyx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks86th Percentile Overall ScoreARDX MarketRank™: Ardelyx scored higher than 86% of companies evaluated by MarketBeat, and ranked 156th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingArdelyx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageArdelyx has only been the subject of 4 research reports in the past 90 days.Read more about Ardelyx's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ardelyx are expected to grow in the coming year, from ($0.18) to $0.31 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ardelyx is -26.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ardelyx is -26.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArdelyx has a P/B Ratio of 10.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Ardelyx's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.44% of the float of Ardelyx has been sold short.Short Interest Ratio / Days to CoverArdelyx has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Ardelyx has recently decreased by 4.89%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArdelyx does not currently pay a dividend.Dividend GrowthArdelyx does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.32 Percentage of Shares Shorted11.44% of the float of Ardelyx has been sold short.Short Interest Ratio / Days to CoverArdelyx has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Ardelyx has recently decreased by 4.89%, indicating that investor sentiment is improving. News and Social Media2.9 / 5News Sentiment1.21 News SentimentArdelyx has a news sentiment score of 1.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Ardelyx this week, compared to 7 articles on an average week.Search InterestOnly 9 people have searched for ARDX on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.MarketBeat Follows9 people have added Ardelyx to their MarketBeat watchlist in the last 30 days. This is an increase of 29% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Ardelyx insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,464,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.80% of the stock of Ardelyx is held by insiders.Percentage Held by Institutions58.92% of the stock of Ardelyx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ardelyx's insider trading history. Receive ARDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter. Email Address ARDX Stock News HeadlinesArdelyx, Inc. (NASDAQ:ARDX) Receives $11.50 Consensus Target Price from BrokeragesAugust 22 at 2:31 AM | americanbankingnews.comArdelyx: Improved Outlook For Ibsrela And XphozahAugust 15, 2025 | seekingalpha.comWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was projected. According to Porter Stansberry, this is panic-level borrowing… and a clear sign we’re nearing America’s financial breaking point. In his latest emergency briefing, Porter outlines why the cracks in our system are widening fast—and how Trump’s policies may be accelerating the collapse. More importantly, he reveals three moves you can make now to protect and potentially grow your wealth before the levee breaks. | Porter & Company (Ad)4 Analysts Assess Ardelyx: What You Need To KnowAugust 7, 2025 | benzinga.comArdelyx Stock Soars On Price Target Hikes After Upbeat Q2 Report: Retail Sees More Revisions ComingAugust 5, 2025 | msn.comArdelyx, Inc. (ARDX) Q2 2025 Earnings Call TranscriptAugust 4, 2025 | seekingalpha.comArdelyx Announces Changes to the Executive Leadership TeamAugust 4, 2025 | globenewswire.comArdelyx Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 4, 2025 | globenewswire.comSee More Headlines ARDX Stock Analysis - Frequently Asked Questions How have ARDX shares performed this year? Ardelyx's stock was trading at $5.07 at the start of the year. Since then, ARDX shares have increased by 20.5% and is now trading at $6.11. How were Ardelyx's earnings last quarter? Ardelyx, Inc. (NASDAQ:ARDX) released its quarterly earnings data on Monday, August, 4th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.05. The business's revenue was up 23.0% on a year-over-year basis. Read the conference call transcript. Who are Ardelyx's major shareholders? Top institutional investors of Ardelyx include Marshall Wace LLP (4.67%), Geode Capital Management LLC (2.35%), Bank of America Corp DE (2.29%) and AQR Capital Management LLC (0.96%). Insiders that own company stock include David M Mott, Michael Raab, Justin A Renz, Laura A Williams, Susan Rodriguez, Robert Blanks, Eric Duane Foster, Elizabeth A Grammer, Mike Kelliher, David P Rosenbaum and Robert Ora Felsch. View institutional ownership trends. How do I buy shares of Ardelyx? Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ardelyx own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ardelyx investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), e.l.f. Beauty (ELF), GE Aerospace (GE), Builders FirstSource (BLDR) and ServiceNow (NOW). Company Calendar Last Earnings8/04/2025Today8/24/2025Next Earnings (Estimated)10/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARDX CIK1437402 Webwww.ardelyx.com Phone(510) 745-1700Fax510-745-0493Employees90Year Founded2007Price Target and Rating Average Price Target for Ardelyx$11.50 High Price Target$15.00 Low Price Target$8.00 Potential Upside/Downside+88.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($0.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$39.14 million Net Margins-14.60% Pretax Margin-14.36% Return on Equity-36.57% Return on Assets-13.42% Debt Debt-to-Equity Ratio1.44 Current Ratio4.30 Quick Ratio4.03 Sales & Book Value Annual Sales$333.61 million Price / Sales4.41 Cash FlowN/A Price / Cash FlowN/A Book Value$0.58 per share Price / Book10.53Miscellaneous Outstanding Shares240,980,000Free Float229,416,000Market Cap$1.47 billion OptionableOptionable Beta0.68 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:ARDX) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...Behind the Markets | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ardelyx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ardelyx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.